Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D Studies

Christiane Drechsler; Graciela Delgado; Christoph Wanner; Katja Blouin; Stefan Pilz; Andreas Tomaschitz; Marcus E. Kleber; Alexander Dressel; Christoph Willmes; Vera Krane; Bernhard K. Kraemer; Winfried Maerz; Eberhard Ritz; Wiek H. van Gilst; Pim van der Harst; Rudolf A. de Boer

doi:10.1681/ASN.2014010093

Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D Studies

Christiane Drechsler^*, Graciela Delgado, Christoph Wanner, Katja Blouin, Stefan Pilz, Andreas Tomaschitz, Marcus E. Kleber, Alexander Dressel, Christoph Willmes, Vera Krane, Bernhard K. Kraemer, Winfried Maerz, Eberhard Ritz, Wiek H. van Gilst, Pim van der Harst, Rudolf A. de Boer

^*Corresponding author for this work

Cardiovascular Centre (CVC)

Research output: Contribution to journal › Article › Academic › peer-review

119 Citations (Scopus)

Abstract

Galectin-3 has been linked to incident renal disease, experimental renal fibrosis, and nephropathy. However, the association among galectin-3, renal function, and adverse outcomes has not been described. We studied this association in two large cohorts of patients over a broad range of renal function. We measured galectin-3 concentrations in baseline samples from the German Diabetes mellitus Dialysis (4D) study (1168 dialysis patients with type 2 diabetes mellitus) and the Ludwigshafen Risk and Cardiovascular Health (LURIC) study (2579 patients with coronary angiograms). Patients were stratified into three groups: eGFR of >= 90 ml/min per 1.73 m2, 60-89 ml/min per 1.73 m(2), and

Original language	English
Pages (from-to)	2213-2221
Number of pages	9
Journal	Journal of the American Society of Nephrology
Volume	26
Issue number	9
DOIs	https://doi.org/10.1681/ASN.2014010093
Publication status	Published - Sept-2015

Keywords

HEART-FAILURE
ATHEROSCLEROTIC LESIONS
FIBROSIS
EXPRESSION
MARKER
PROGRESSION
DISEASE
KIDNEY
MICE
RAT

Access to Document

10.1681/ASN.2014010093

Handle.net

Persistent link

Embargoed Document

Galectin-3, Renal Function, and Clinical Outcomes Results from the LURIC
Final publisher's version, 783 KB
Request copy

Cite this

Drechsler, C., Delgado, G., Wanner, C., Blouin, K., Pilz, S., Tomaschitz, A., Kleber, M. E., Dressel, A., Willmes, C., Krane, V., Kraemer, B. K., Maerz, W., Ritz, E., van Gilst, W. H., van der Harst, P., & de Boer, R. A. (2015). Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D Studies. Journal of the American Society of Nephrology, 26(9), 2213-2221. https://doi.org/10.1681/ASN.2014010093

@article{22c1004bef3042299ef736f5b9a911f4,

title = "Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D Studies",

abstract = "Galectin-3 has been linked to incident renal disease, experimental renal fibrosis, and nephropathy. However, the association among galectin-3, renal function, and adverse outcomes has not been described. We studied this association in two large cohorts of patients over a broad range of renal function. We measured galectin-3 concentrations in baseline samples from the German Diabetes mellitus Dialysis (4D) study (1168 dialysis patients with type 2 diabetes mellitus) and the Ludwigshafen Risk and Cardiovascular Health (LURIC) study (2579 patients with coronary angiograms). Patients were stratified into three groups: eGFR of >= 90 ml/min per 1.73 m2, 60-89 ml/min per 1.73 m(2), and",

keywords = "HEART-FAILURE, ATHEROSCLEROTIC LESIONS, FIBROSIS, EXPRESSION, MARKER, PROGRESSION, DISEASE, KIDNEY, MICE, RAT",

author = "Christiane Drechsler and Graciela Delgado and Christoph Wanner and Katja Blouin and Stefan Pilz and Andreas Tomaschitz and Kleber, {Marcus E.} and Alexander Dressel and Christoph Willmes and Vera Krane and Kraemer, {Bernhard K.} and Winfried Maerz and Eberhard Ritz and {van Gilst}, {Wiek H.} and {van der Harst}, Pim and {de Boer}, {Rudolf A.}",

year = "2015",

month = sep,

doi = "10.1681/ASN.2014010093",

language = "English",

volume = "26",

pages = "2213--2221",

journal = "Journal of the American Society of Nephrology",

issn = "1046-6673",

publisher = "AMER SOC NEPHROLOGY",

number = "9",

}

Drechsler, C, Delgado, G, Wanner, C, Blouin, K, Pilz, S, Tomaschitz, A, Kleber, ME, Dressel, A, Willmes, C, Krane, V, Kraemer, BK, Maerz, W, Ritz, E, van Gilst, WH , van der Harst, P & de Boer, RA 2015, 'Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D Studies', Journal of the American Society of Nephrology, vol. 26, no. 9, pp. 2213-2221. https://doi.org/10.1681/ASN.2014010093

TY - JOUR

T1 - Galectin-3, Renal Function, and Clinical Outcomes

T2 - Results from the LURIC and 4D Studies

AU - Drechsler, Christiane

AU - Delgado, Graciela

AU - Wanner, Christoph

AU - Blouin, Katja

AU - Pilz, Stefan

AU - Tomaschitz, Andreas

AU - Kleber, Marcus E.

AU - Dressel, Alexander

AU - Willmes, Christoph

AU - Krane, Vera

AU - Kraemer, Bernhard K.

AU - Maerz, Winfried

AU - Ritz, Eberhard

AU - van Gilst, Wiek H.

AU - van der Harst, Pim

AU - de Boer, Rudolf A.

PY - 2015/9

Y1 - 2015/9

N2 - Galectin-3 has been linked to incident renal disease, experimental renal fibrosis, and nephropathy. However, the association among galectin-3, renal function, and adverse outcomes has not been described. We studied this association in two large cohorts of patients over a broad range of renal function. We measured galectin-3 concentrations in baseline samples from the German Diabetes mellitus Dialysis (4D) study (1168 dialysis patients with type 2 diabetes mellitus) and the Ludwigshafen Risk and Cardiovascular Health (LURIC) study (2579 patients with coronary angiograms). Patients were stratified into three groups: eGFR of >= 90 ml/min per 1.73 m2, 60-89 ml/min per 1.73 m(2), and

AB - Galectin-3 has been linked to incident renal disease, experimental renal fibrosis, and nephropathy. However, the association among galectin-3, renal function, and adverse outcomes has not been described. We studied this association in two large cohorts of patients over a broad range of renal function. We measured galectin-3 concentrations in baseline samples from the German Diabetes mellitus Dialysis (4D) study (1168 dialysis patients with type 2 diabetes mellitus) and the Ludwigshafen Risk and Cardiovascular Health (LURIC) study (2579 patients with coronary angiograms). Patients were stratified into three groups: eGFR of >= 90 ml/min per 1.73 m2, 60-89 ml/min per 1.73 m(2), and

KW - HEART-FAILURE

KW - ATHEROSCLEROTIC LESIONS

KW - FIBROSIS

KW - EXPRESSION

KW - MARKER

KW - PROGRESSION

KW - DISEASE

KW - KIDNEY

KW - MICE

KW - RAT

U2 - 10.1681/ASN.2014010093

DO - 10.1681/ASN.2014010093

M3 - Article

SN - 1046-6673

VL - 26

SP - 2213

EP - 2221

JO - Journal of the American Society of Nephrology

JF - Journal of the American Society of Nephrology

IS - 9

ER -

Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D Studies

Abstract

Keywords

Access to Document

Handle.net

Embargoed Document

Fingerprint

Cite this